Experienced in Metastatic Brain Tumor

Nicolas U. Gerber

Zurich, ZH, CH 
Experienced in Metastatic Brain Tumor
Zurich, ZH, CH 
OverviewLocationsClinical Research

Overview

Nicolas Gerber practices in Zurich, Switzerland. Mr. Gerber is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, Gliomatosis Cerebri, Medulloblastoma, and Osteotomy.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Zurich, ZH, Switzerland
Other Locations
Bern, BE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug, Procedure
Study Drug: Fimepinostat
Study Phase: Early Phase 1
H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC With and Without PD-1 Inhibition Using Nivolumab for the Treatment of Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Gliomas
H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC With and Without PD-1 Inhibition Using Nivolumab for the Treatment of Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and Newly Diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Gliomas
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Biological, Drug
Study Drugs: K27M Peptide, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Temozolomide, Irinotecan, Topotecan, Dinutuximab Beta, Cyclophosphamide
Study Phase: Phase 2
Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Enrollment Status: Terminated
Publish Date: May 31, 2022
Intervention Type: Drug
Study Drugs: Vinblastine+Nilotinib, Vinblastine
Study Phase: Phase 2
PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Drug
Study Drugs: Nilotinib, Vinblastine
Study Phase: Phase 1
View 4 Less Clinical Trials

116 Total Publications

Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries.
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries.
Journal: Neuro-oncology
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gerber's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile